Since the target engagement was considered achieved if at least two of three genes demonstrated a twofold or greater change induction (HEXIM1 and HIST2H2BF) or suppression (CCR2) compared with baseline, target engagement was seen at all dose levels in phase Ia DLBCL patient blood samples. This evidence concerns the gene CCR2 and diffuse large B-cell lymphoma.